Educational only. This page is not legal, medical, import or purchasing advice.
The basic distinction
In Canada, readers should separate approved prescription medicines from research-use-only compounds and from consumer wellness claims. A peptide can be discussed in research literature without being approved, appropriate, or lawful for consumer use.
What Canadian readers should verify
- Whether the compound is an approved prescription medicine in Canada.
- Whether a product is labeled clearly for research use only.
- Whether the supplier publishes batch-specific COAs.
- Whether the COA includes identity and purity testing.
- Whether any health claim goes beyond the available evidence.
GLP-1 medicines are different
Semaglutide and tirzepatide sit in a different category than gray-market research peptides because they have regulated prescription pathways for approved indications. PRN treats those pages separately from research-use supplier pages.
Where PRN is going next
The Canada section will become a hub for Health Canada context, supplier testing standards, COA education, Canadian GLP-1 access resources and plain language research summaries.